Last updated: February 25, 2026
What is OMNISCAN and Its Market Position?
OMNISCAN (iodine-based contrast agent) is used primarily for diagnostic imaging procedures, including enhanced computed tomography (CT) scans. It is formulated for intravenous injection. The global contrast media market in medical imaging is projected to grow at a CAGR of 4-6% from 2023 to 2030, driven by increasing demand for diagnostic procedures and technological advancements[1].
OMNISCAN faces competition from both iodinated contrast agents and alternative imaging modalities like MRI and ultrasound that do not require contrast media. Its positioning hinges on safety profile, imaging efficacy, and ease of administration.
Excipient Components in OMNISCAN
OMNISCAN formulations typically include the following excipients:
- Iodine-based contrast agent (active pharmaceutical ingredient)
- Water for injection (solvent)
- Buffering agents (e.g., sodium chloride or sodium bicarbonate) to maintain pH balance
- Stabilizers and preservatives (e.g., sodium benzoate) to prevent microbial growth
- Osmotic agents may be added to match blood osmolarity
The excipient choice influences not only formulation stability but also the safety, tolerability, and total manufacturing cost.
Excipient Strategies for Optimization and Differentiation
1. Reducing Osmolality
- Traditional ionic contrast agents have high osmolality (~700-1500 mOsm/kg), which causes adverse reactions.
- Non-ionic contrast agents like OMNISCAN aim for iso- or low-osmolar formulations (~300-600 mOsm/kg) to improve safety.
Implication: Developing excipient combinations that lower osmolarity can expand patient safety profiles and market appeal.
2. Stabilizer Innovation
- Using novel stabilizers to enhance shelf life and prevent degradation.
- Replacing preservatives with derivatives less likely to cause allergic reactions.
Impact: Improves product stability, reduces side effects, and aligns with regulatory expectations.
3. Buffer System Optimization
- Adjusting buffering agents to match physiological pH (~7.4) enhances tolerability.
- Exploring alternative buffers like phosphate or citrate salts.
Benefit: Decreases incidence of adverse reactions related to pH imbalance.
4. Compatibility with Alternative Delivery Modes
- Exploring excipients that enable multiple administration routes or combination therapies.
- Developing compatibility with prefilled syringes to streamline hospital workflows.
Outcome: Greater flexibility can lead to increased adoption in clinical settings.
Commercial Opportunities in Excipient Development
1. Patent and IP Extension
- Innovation in excipient combinations allows for new patent filings, prolonging market exclusivity.
- Formulations with reduced osmolarity or improved stability meet regulatory standards and offer competitive edges.
2. Cost Reduction and Manufacturing Efficiency
- Sourcing alternative excipients that are more cost-effective.
- Simplifying formulation processes to reduce manufacturing time and complexity.
3. Regulatory Premiums
- Meeting or exceeding guidelines set by agencies such as FDA or EMA for safety and tolerability.
- Positioning formulations as safer options to command higher pricing.
4. Expanding Indications and Usage
- Developing excipient profiles compatible with investigational uses or pediatric populations.
- Introducing formulations suitable for patients with specific conditions like renal impairment.
5. Market Expansion
- Entering emerging markets with cost-efficient, safe formulations.
- Collaborating with local manufacturing entities for tailored excipient sourcing.
Regulatory and Manufacturing Considerations
- Excipient safety profiles are scrutinized under ICH Q3D (Elemental Impurities) and other guidelines.
- Formulation changes require review and approval, influencing time-to-market.
- Scaling up requires thorough stability testing of excipient combinations.
Summary Table: Key Excipient Strategies and Opportunities
| Strategy |
Objective |
Market Benefit |
Implementation Consideration |
| Osmolality reduction |
Enhance safety |
Expand patient eligibility |
Excipient compatibility, regulatory validation |
| Stabilizer innovation |
Increase shelf life |
Reduce waste, improve safety |
Compatibility testing, patentability |
| Buffer optimization |
Improve tolerability |
Broaden clinical use |
pH stability, formulation testing |
| Delivery system compatibility |
Increase flexibility |
Drive higher adoption |
Compatibility with devices, regulatory clearance |
| Cost-effective sourcing |
Reduce manufacturing cost |
Price competitiveness |
Supply chain validation, quality standards |
Key Takeaways
- Excipient choices in OMNISCAN influence safety, stability, and market differentiation.
- Innovation aimed at lowering osmolality and improving stability offers significant commercial leverage.
- Regulatory compliance and stability are critical in formulating and sourcing excipients.
- Opportunities exist in patent extension, cost reduction, and expanding indications through excipient strategies.
- Market growth in diagnostic imaging supports ongoing development and commercialization efforts.
FAQs
1. What excipients are most critical in OMNISCAN formulation?
Water, buffering agents, preservatives, stabilizers, and osmotic agents are essential for stability, safety, and efficacy.
2. How does excipient choice affect OMNISCAN safety profile?
Excipients impact osmolarity, pH, and microbial stability, influencing adverse reactions and tolerability.
3. Are low-osmolar formulations more profitable?
Yes. They typically command higher prices and expand market access due to improved safety profiles.
4. What regulatory hurdles exist for excipient modifications?
Changes require stability studies, safety data, and regulatory submissions (e.g., NDA amendments).
5. Can excipient innovation extend OMNISCAN’s patent life?
Yes. Novel formulations with unique excipient combinations can be patented, extending exclusivity.
References
[1] Markets and Markets. (2022). Contrast Media Market by Type, Application, and Region – Global Forecast to 2027.
